Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function.
Several lines of evidence have suggested a link between serotonergic and dopaminergic systems in the brain. The interpretation of much of these early data needs careful reevaluation in light of the recent understanding of the plethora of serotonin receptor subtypes, their distribution in the brain and the new findings with more selective serotonin antagonists. Electrophysiological, biochemical and behavioral evidence obtained using highly selective antagonists of the 5-HT2 or 5-HT3 receptor subtypes, MDL 100,907 or MDL 73,147EF, respectively, supports the thesis that serotonin modulates the dopaminergic system. This modulation is most evident when the dopaminergic system has been activated.
Palfreyman
M G
MG
Marion Merrell Dow Research Institute, Cincinnati, OH 45215.
Schmidt
C J
CJ
Sorensen
S M
SM
Dudley
M W
MW
Kehne
J H
JH
Moser
P
P
Gittos
M W
MW
Carr
A A
AA
D000818:Animals; D001480:Basal Ganglia Diseases / Q000503:physiopathology; D001522:Behavior, Animal / Q000187:drug effects / Q000502:physiology*; D004298:Dopamine / Q000502:physiology*; D004594:Electrophysiology; D005464:Fluorobenzenes / Q000494:pharmacology; D007211:Indoles / Q000494:pharmacology; D008297:Male; D051379:Mice; D017551:Microdialysis; D009043:Motor Activity / Q000187:drug effects; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000494:pharmacology; D009474:Neurons / Q000187:drug effects; D010880:Piperidines / Q000494:pharmacology; D011807:Quinolizines / Q000494:pharmacology; D051381:Rats; D017207:Rats, Sprague-Dawley; D011985:Receptors, Serotonin / Q000378:metabolism / Q000502:physiology*; D012702:Serotonin Antagonists / Q000494:pharmacology
D005464:Fluorobenzenes; D007211:Indoles; D010880:Piperidines; D011807:Quinolizines; D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; C060344:dolasetron; C079049:volinanserin; D018817:N-Methyl-3,4-methylenedioxyamphetamine; D004298:Dopamine